By Ben GlickmanHilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief. The Boston-based biopharmaceutical company said that co-founder and current COO Aditya Kohli will become chief business officer as part of a planned transition. McLoughlin, 52, recently served as global vaccine commercialization lead, RSV at GSK. He has held various roles at GSK over 25 years with the company. McLoughlin will receive an annual base salary of $450,000, with an annual target bonus of 45% of his salary and a sign-on bonus of $200,000.

Source: Wall Street Journal January 18, 2024 18:38 UTC